Kevin Bitterman Sells 1,425 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 1,425 shares of the company’s stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $77.11, for a total transaction of $109,881.75. Following the completion of the transaction, the director owned 477,036 shares in the company, valued at $36,784,245.96. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kevin Bitterman also recently made the following trade(s):

• On Friday, October 17th, Kevin Bitterman sold 70,000 shares of Disc Medicine stock. The stock was sold at an average price of $88.91, for a total transaction of $6,223,700.00.
• On Wednesday, October 15th, Kevin Bitterman sold 22,160 shares of Disc Medicine stock. The stock was sold at an average price of $77.23, for a total transaction of $1,711,416.80.
• On Wednesday, October 8th, Kevin Bitterman sold 71,961 shares of Disc Medicine stock. The shares were sold at an average price of $70.58, for a total transaction of $5,079,007.38.
• On Tuesday, October 7th, Kevin Bitterman sold 18,039 shares of Disc Medicine stock. The shares were sold at an average price of $68.38, for a total value of $1,233,506.82.
• On Friday, August 22nd, Kevin Bitterman sold 2,287 shares of Disc Medicine stock. The stock was sold at an average price of $61.03, for a total value of $139,575.61.
• On Thursday, August 14th, Kevin Bitterman sold 7,212 shares of Disc Medicine stock. The shares were sold at an average price of $60.99, for a total value of $439,859.88.
• On Wednesday, August 13th, Kevin Bitterman sold 24,962 shares of Disc Medicine stock. The stock was sold at an average price of $61.15, for a total value of $1,526,426.30.
• On Tuesday, August 5th, Kevin Bitterman sold 395 shares of Disc Medicine stock. The stock was sold at an average price of $60.95, for a total value of $24,075.25.
• On Wednesday, July 30th, Kevin Bitterman sold 8,492 shares of Disc Medicine stock. The stock was sold at an average price of $61.04, for a total transaction of $518,351.68.
• On Thursday, July 24th, Kevin Bitterman sold 13,033 shares of Disc Medicine stock. The stock was sold at an average price of $61.17, for a total transaction of $797,228.61.

Disc Medicine Price Performance

IRON stock opened at $89.94 on Friday. The company’s 50-day moving average price is $63.69 and its two-hundred day moving average price is $54.76. The firm has a market cap of $3.13 billion, a P/E ratio of -20.12 and a beta of 0.80. The company has a quick ratio of 32.11, a current ratio of 32.11 and a debt-to-equity ratio of 0.05. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $95.95.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.41). On average, analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a research note on Thursday, July 3rd. National Bankshares set a $153.00 target price on Disc Medicine in a research report on Friday. Morgan Stanley increased their target price on shares of Disc Medicine from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Monday, August 18th. Truist Financial started coverage on shares of Disc Medicine in a research note on Monday, July 21st. They issued a “buy” rating and a $86.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $108.73.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently made changes to their positions in IRON. GAMMA Investing LLC increased its stake in shares of Disc Medicine by 5,092.5% in the first quarter. GAMMA Investing LLC now owns 12,410 shares of the company’s stock valued at $616,000 after buying an additional 12,171 shares during the period. Rhumbline Advisers grew its holdings in Disc Medicine by 10.7% during the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company’s stock worth $1,596,000 after acquiring an additional 3,108 shares during the last quarter. SG Americas Securities LLC grew its holdings in Disc Medicine by 77.4% during the 1st quarter. SG Americas Securities LLC now owns 14,329 shares of the company’s stock worth $711,000 after acquiring an additional 6,253 shares during the last quarter. Amalgamated Bank increased its position in Disc Medicine by 38.6% in the 1st quarter. Amalgamated Bank now owns 787 shares of the company’s stock valued at $39,000 after acquiring an additional 219 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Disc Medicine by 10.9% during the first quarter. Bank of New York Mellon Corp now owns 63,503 shares of the company’s stock valued at $3,152,000 after acquiring an additional 6,242 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.